Genmab's revenue reaches DKK 7bn in first half of 2023
Both revenue and earnings are higher in the first six months of the year than last year for Genmab, which has just raised its full-year guidance.
Genmab ended the first half of 2023 with revenues of DKK 7.1bn and net earnings of DKK 1.6bn. In comparison, the company had revenue of DKK 5.3bn and a bottom line of DKK 2.4bn in the same six months last year. This is according to Genmab’s half-year results, which the company presented on Thursday afternoon.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab raises guidance for 2023 after strong Darzalex sales
For subscribers
Genmab moves headquarters
For subscribers
